Abstract
In a prospective, randomized study, 110 adults receiving aminogly-cosides were randomized to follow-up by a clinical pharmacokinetic service (CPS). Of the 110 patients, 35 accepted pharmacokinetic recommendations less than 100% of the time. The two groups were similar in age, sex, height, APACHE II score, and initial creatinine clearance. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Patients whose physicians accepted pharmacokinetic recommendations 100% of the time had shorter hospitalizations (322.67 ± 270.28 h; CPS <100%, 699.54 ± 806.35; p = 0.001) and febrile periods (50.05 ± 79.38 h; CPS <100%, 120.00 ± 153.23; p = 0.002). Acceptance of CPS recommendations led to adequate peak levels. Acceptance of CPS recommendations led to lower direct costs (7,102.56 ± 9,898.19; CPS <100%, 19,629.94 ± 28,051.89; p <0.001). Calculated direct cost of the service was 85/patient.
| Original language | English |
|---|---|
| Pages (from-to) | 427-433 |
| Number of pages | 7 |
| Journal | Therapeutic Drug Monitoring |
| Volume | 12 |
| Issue number | 5 |
| State | Published - 1990 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Health, Toxicology and Mutagenesis
- Public Health, Environmental and Occupational Health
- Toxicology
Cite this
Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. / Destache, Christopher J.; Meyer, Sharon K.; Rowley, Karen M.
In: Therapeutic Drug Monitoring, Vol. 12, No. 5, 1990, p. 427-433.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis
AU - Destache, Christopher J.
AU - Meyer, Sharon K.
AU - Rowley, Karen M.
PY - 1990
Y1 - 1990
N2 - In a prospective, randomized study, 110 adults receiving aminogly-cosides were randomized to follow-up by a clinical pharmacokinetic service (CPS). Of the 110 patients, 35 accepted pharmacokinetic recommendations less than 100% of the time. The two groups were similar in age, sex, height, APACHE II score, and initial creatinine clearance. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Patients whose physicians accepted pharmacokinetic recommendations 100% of the time had shorter hospitalizations (322.67 ± 270.28 h; CPS <100%, 699.54 ± 806.35; p = 0.001) and febrile periods (50.05 ± 79.38 h; CPS <100%, 120.00 ± 153.23; p = 0.002). Acceptance of CPS recommendations led to adequate peak levels. Acceptance of CPS recommendations led to lower direct costs (7,102.56 ± 9,898.19; CPS <100%, 19,629.94 ± 28,051.89; p <0.001). Calculated direct cost of the service was 85/patient.
AB - In a prospective, randomized study, 110 adults receiving aminogly-cosides were randomized to follow-up by a clinical pharmacokinetic service (CPS). Of the 110 patients, 35 accepted pharmacokinetic recommendations less than 100% of the time. The two groups were similar in age, sex, height, APACHE II score, and initial creatinine clearance. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Patients whose physicians accepted pharmacokinetic recommendations 100% of the time had shorter hospitalizations (322.67 ± 270.28 h; CPS <100%, 699.54 ± 806.35; p = 0.001) and febrile periods (50.05 ± 79.38 h; CPS <100%, 120.00 ± 153.23; p = 0.002). Acceptance of CPS recommendations led to adequate peak levels. Acceptance of CPS recommendations led to lower direct costs (7,102.56 ± 9,898.19; CPS <100%, 19,629.94 ± 28,051.89; p <0.001). Calculated direct cost of the service was 85/patient.
UR - http://www.scopus.com/inward/record.url?scp=0025091532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025091532&partnerID=8YFLogxK
M3 - Article
C2 - 2127325
AN - SCOPUS:0025091532
VL - 12
SP - 427
EP - 433
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
SN - 0163-4356
IS - 5
ER -